FVB.Cg-Col18a1tm1Pih/Oulu

Status

Available to order

EMMA IDEM:15977
Citation informationRRID:IMSR_EM:15977 

Research Resource Identifiers (RRID) are persistent unique ID numbers assigned to help researchers cite key resources (e.g. antibodies, model organisms and software projects) in the biomedical literature to improve transparency and reproducibility in research. See https://www.rrids.org/ for more information.

 
International strain nameFVB.Cg-Col18a1tm1Pih/Oulu
Alternative nameCol18a1tm1Pih; Col18a1-P1
Strain typeTargeted Mutant Strains : Other targeted
Allele/Transgene symbolCol18a1tm1Pih
Gene/Transgene symbolCol18a1

Information from provider

ProviderTaina Pihlajaniemi
Provider affiliationFaculty of Biochemistry and Molecular Medicine, University of Oulu
Genetic informationExon 1 of Col18a1 was deleted to form a promoter 1 (P1)-specific knockout in which the short collagen XVIII isoform is inactivated while the medium and long collagen XVIII isoforms are expressed.
Phenotypic informationHomozygous:
Phenotypic characterization of the Col18a1-P1 FVB/N mice has not been done. Breast cancer growth and metastasis is significantly reduced in the Col18a1-P1 FVB/N null mice crossed with the MMTV-PyMT (Tg(MMTV-PyVT)634Mul, MGI:2679595) transgenic model. The FVB/N background might be useful e.g. in some cancer models such as DMBA-TPA induced skin carcinogenesis which does not work well in the C57BL/6 background, or with the MMVT-PyMT model as we have used.

Heterozygous:
Heterozygous mice are normal.
Breeding historyGene targeting was performed in 129/Sv embryonic stem cells and the resulting mice were backcrossed at least 10 times to C57BL/6JOlaHsd background and further to FVB/NCrl background for 8 generations.
References
  • Targeting collagen XVIII improves the efficiency of ErbB inhibitors in breast cancer models.;Devarajan Raman, Izzi Valerio, Peltoketo Hellevi, Rask Gunilla, Kauppila Saila, Väisänen Marja-Riitta, Ruotsalainen Heli, Martínez-Nieto Guillermo, Karppinen Sanna-Maria, Väisänen Timo, Kaur Inderjeet, Koivunen Jussi, Sasaki Takako, Winqvist Robert, Manninen Aki, Wärnberg Fredrik, Sund Malin, Pihlajaniemi Taina, Heljasvaara Ritva, ;2023;The Journal of clinical investigation;133;; 37498672
Homozygous fertileyes
Homozygous viableyes
Homozygous matings requiredno
Immunocompromisedno

Information from EMMA

Archiving centreUniversity of Oulu, Oulu, Finland

Disease and phenotype information

Orphanet associated rare diseases, based on orthologous gene matching

IMPC phenotypes (gene matching)
  • abnormal retina vasculature morphology / IMPC
  • abnormal optic disk morphology / IMPC
  • increased vertical activity / IMPC
  • abnormal placement of pupils / IMPC
  • decreased circulating HDL cholesterol level / IMPC
  • abnormal lens morphology / IMPC
  • increased circulating free fatty acids level / IMPC
  • abnormal retina blood vessel morphology / IMPC
  • decreased circulating glucose level / IMPC
  • hyperactivity / IMPC
  • increased circulating triglyceride level / IMPC
  • irregularly shaped pupil / IMPC
  • abnormal iris pigmentation / IMPC
  • abnormal retina morphology / IMPC
  • increased fasting circulating glucose level / IMPC
MGI phenotypes (gene matching)
  • abnormal cranium morphology / MGI
  • enlarged cranium / MGI
  • abnormal choroid plexus morphology / MGI
  • dilated lateral ventricles / MGI
  • dilated third ventricle / MGI
  • dilated fourth ventricle / MGI
  • persistence of hyaloid vascular system / MGI
  • abnormal pupil morphology / MGI
  • abnormal iris morphology / MGI
  • abnormal retina morphology / MGI
  • increased circulating triglyceride level / MGI
  • abnormal circulating enzyme level / MGI
  • hydroencephaly / MGI
  • intracranial hemorrhage / MGI
  • neoplasm / MGI
  • abnormal brain morphology / MGI
  • abnormal tricuspid valve morphology / MGI
  • abnormal vitreous body morphology / MGI
  • abnormal retinal vasculature morphology / MGI
  • increased circulating VLDL triglyceride level / MGI
  • abnormal basement membrane morphology / MGI
  • abnormal proximal convoluted tubule morphology / MGI
  • abnormal ciliary body morphology / MGI
  • abnormal iris pigment epithelium / MGI
  • abnormal enzyme/coenzyme level / MGI
  • abnormal renal glomerulus morphology / MGI
  • renal/urinary system phenotype / MGI
  • abnormal iris stromal pigmentation / MGI
  • increased circulating creatinine level / MGI
  • abnormal corneal epithelium morphology / MGI
  • impaired lipolysis / MGI
  • podocyte foot process effacement / MGI
  • abnormal brain ependyma motile cilium morphology / MGI
  • abnormal mesangial matrix morphology / MGI
  • expanded mesangial matrix / MGI
  • enlarged brain ventricles / MGI

Literature references

  • Targeting collagen XVIII improves the efficiency of ErbB inhibitors in breast cancer models.;Devarajan Raman, Izzi Valerio, Peltoketo Hellevi, Rask Gunilla, Kauppila Saila, Väisänen Marja-Riitta, Ruotsalainen Heli, Martínez-Nieto Guillermo, Karppinen Sanna-Maria, Väisänen Timo, Kaur Inderjeet, Koivunen Jussi, Sasaki Takako, Winqvist Robert, Manninen Aki, Wärnberg Fredrik, Sund Malin, Pihlajaniemi Taina, Heljasvaara Ritva, ;2023;The Journal of clinical investigation;133;; 37498672

Information on how we integrate external resources can be found here

Order

Availabilities

Requesting frozen sperm or embryos is generally advisable wherever possible, in order to minimise the shipment of live mice.

  • Frozen sperm. Delivered in 4 weeks (after paperwork in place). €1740*
  • Rederivation of mice from frozen stock, delivery time available upon request . €3880*

Due to the dynamic nature of our processes strain availability may change at short notice. The local repository manager will advise you in these circumstances.

* In addition users have to cover all the shipping costs (including the cost for returning dry-shippers, where applicable).

More details on pricing and delivery times

Practical information

Example health report
(Current health report will be provided later)

Material Transfer Agreement (MTA)
Distribution of this strain is subject to a provider MTA. Both signing of the MTA and submission of the online EMMA Mutant Request Form are required before material can be shipped.

EMMA conditions
Legally binding conditions for the transfer

Right strain for your research?

The information provided on this page is, to the best of EMMA’s knowledge, based on data supplied by the original provider. End users are responsible for reviewing these details and for validating the strain and its suitability for their experimental use.​
Not found what you were looking for? Search here for other strains available from EMMA.


Search
INFRAFRONTIER® and European Mouse Mutant Archive - EMMA® are registered trademarks at the European Union Intellectual Property Office (EUIPO).